Conolidine’s analgesic effects stem from its conversation with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors while in the central anxious process, conolidine modulates alternate molecular targets. A Science Improvements review discovered that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://englandg541def3.bloggazza.com/profile